当前位置: 首页 >> 检索结果
1861. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
作者: Olivier L Chinot.;Wolfgang Wick.;Warren Mason.;Roger Henriksson.;Frank Saran.;Ryo Nishikawa.;Antoine F Carpentier.;Khe Hoang-Xuan.;Petr Kavan.;Dana Cernea.;Alba A Brandes.;Magalie Hilton.;Lauren Abrey.;Timothy Cloughesy.
来源: N Engl J Med. 2014年370卷8期709-22页
Standard therapy for newly diagnosed glioblastoma is radiotherapy plus temozolomide. In this phase 3 study, we evaluated the effect of the addition of bevacizumab to radiotherapy-temozolomide for the treatment of newly diagnosed glioblastoma.
1862. A randomized trial of bevacizumab for newly diagnosed glioblastoma.
作者: Mark R Gilbert.;James J Dignam.;Terri S Armstrong.;Jeffrey S Wefel.;Deborah T Blumenthal.;Michael A Vogelbaum.;Howard Colman.;Arnab Chakravarti.;Stephanie Pugh.;Minhee Won.;Robert Jeraj.;Paul D Brown.;Kurt A Jaeckle.;David Schiff.;Volker W Stieber.;David G Brachman.;Maria Werner-Wasik.;Ivo W Tremont-Lukats.;Erik P Sulman.;Kenneth D Aldape.;Walter J Curran.;Minesh P Mehta.
来源: N Engl J Med. 2014年370卷8期699-708页
Concurrent treatment with temozolomide and radiotherapy followed by maintenance temozolomide is the standard of care for patients with newly diagnosed glioblastoma. Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor A, is currently approved for recurrent glioblastoma. Whether the addition of bevacizumab would improve survival among patients with newly diagnosed glioblastoma is not known.
1863. Comparison of pregabalin with pramipexole for restless legs syndrome.
作者: Richard P Allen.;Crystal Chen.;Diego Garcia-Borreguero.;Olli Polo.;Sarah DuBrava.;Jeffrey Miceli.;Lloyd Knapp.;John W Winkelman.
来源: N Engl J Med. 2014年370卷7期621-31页
Dopaminergic medications relieve symptoms of the restless legs syndrome (RLS) but have the potential to cause iatrogenic worsening (augmentation) of RLS with long-term treatment. Pregabalin may be an effective alternative.
1864. Oxantel pamoate-albendazole for Trichuris trichiura infection.
作者: Benjamin Speich.;Shaali M Ame.;Said M Ali.;Rainer Alles.;Jörg Huwyler.;Jan Hattendorf.;Jürg Utzinger.;Marco Albonico.;Jennifer Keiser.
来源: N Engl J Med. 2014年370卷7期610-20页
Infections with soil-transmitted helminths (Ascaris lumbricoides, hookworm, and Trichuris trichiura) are widespread and often occur concomitantly. These parasitic-worm infections are typically treated with albendazole or mebendazole, but both drugs show low efficacy against T. trichiura. Albendazole is the drug of choice against hookworm.
1865. Final trial report of sentinel-node biopsy versus nodal observation in melanoma.
作者: Donald L Morton.;John F Thompson.;Alistair J Cochran.;Nicola Mozzillo.;Omgo E Nieweg.;Daniel F Roses.;Harold J Hoekstra.;Constantine P Karakousis.;Christopher A Puleo.;Brendon J Coventry.;Mohammed Kashani-Sabet.;B Mark Smithers.;Eberhard Paul.;William G Kraybill.;J Gregory McKinnon.;He-Jing Wang.;Robert Elashoff.;Mark B Faries.; .
来源: N Engl J Med. 2014年370卷7期599-609页
Sentinel-node biopsy, a minimally invasive procedure for regional melanoma staging, was evaluated in a phase 3 trial.
1866. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
作者: Stephen Salloway.;Reisa Sperling.;Nick C Fox.;Kaj Blennow.;William Klunk.;Murray Raskind.;Marwan Sabbagh.;Lawrence S Honig.;Anton P Porsteinsson.;Steven Ferris.;Marcel Reichert.;Nzeera Ketter.;Bijan Nejadnik.;Volkmar Guenzler.;Maja Miloslavsky.;Daniel Wang.;Yuan Lu.;Julia Lull.;Iulia Cristina Tudor.;Enchi Liu.;Michael Grundman.;Eric Yuen.;Ronald Black.;H Robert Brashear.; .
来源: N Engl J Med. 2014年370卷4期322-33页
Bapineuzumab, a humanized anti-amyloid-beta monoclonal antibody, is in clinical development for the treatment of Alzheimer's disease.
1867. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.
作者: Rachelle S Doody.;Ronald G Thomas.;Martin Farlow.;Takeshi Iwatsubo.;Bruno Vellas.;Steven Joffe.;Karl Kieburtz.;Rema Raman.;Xiaoying Sun.;Paul S Aisen.;Eric Siemers.;Hong Liu-Seifert.;Richard Mohs.; .; .
来源: N Engl J Med. 2014年370卷4期311-21页
Alzheimer's disease is characterized by amyloid-beta plaques, neurofibrillary tangles, gliosis, and neuronal loss. Solanezumab, a humanized monoclonal antibody, preferentially binds soluble forms of amyloid and in preclinical studies promoted its clearance from the brain.
1868. A trial of mass isoniazid preventive therapy for tuberculosis control.
作者: Gavin J Churchyard.;Katherine L Fielding.;James J Lewis.;Leonie Coetzee.;Elizabeth L Corbett.;Peter Godfrey-Faussett.;Richard J Hayes.;Richard E Chaisson.;Alison D Grant.; .
来源: N Engl J Med. 2014年370卷4期301-10页
Tuberculosis is epidemic among workers in South African gold mines. We evaluated an intervention to interrupt tuberculosis transmission by means of mass screening that was linked to treatment for active disease or latent infection.
1869. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.
作者: Ajay K Gopal.;Brad S Kahl.;Sven de Vos.;Nina D Wagner-Johnston.;Stephen J Schuster.;Wojciech J Jurczak.;Ian W Flinn.;Christopher R Flowers.;Peter Martin.;Andreas Viardot.;Kristie A Blum.;Andre H Goy.;Andrew J Davies.;Pier Luigi Zinzani.;Martin Dreyling.;Dave Johnson.;Langdon L Miller.;Leanne Holes.;Daniel Li.;Roger D Dansey.;Wayne R Godfrey.;Gilles A Salles.
来源: N Engl J Med. 2014年370卷11期1008-18页
Phosphatidylinositol-3-kinase delta (PI3Kδ) mediates B-cell receptor signaling and microenvironmental support signals that promote the growth and survival of malignant B lymphocytes. In a phase 1 study, idelalisib, an orally active selective PI3Kδ inhibitor, showed antitumor activity in patients with previously treated indolent non-Hodgkin's lymphomas.
1870. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.
作者: Richard R Furman.;Jeff P Sharman.;Steven E Coutre.;Bruce D Cheson.;John M Pagel.;Peter Hillmen.;Jacqueline C Barrientos.;Andrew D Zelenetz.;Thomas J Kipps.;Ian Flinn.;Paolo Ghia.;Herbert Eradat.;Thomas Ervin.;Nicole Lamanna.;Bertrand Coiffier.;Andrew R Pettitt.;Shuo Ma.;Stephan Stilgenbauer.;Paula Cramer.;Maria Aiello.;Dave M Johnson.;Langdon L Miller.;Daniel Li.;Thomas M Jahn.;Roger D Dansey.;Michael Hallek.;Susan M O'Brien.
来源: N Engl J Med. 2014年370卷11期997-1007页
Patients with relapsed chronic lymphocytic leukemia (CLL) who have clinically significant coexisting medical conditions are less able to undergo standard chemotherapy. Effective therapies with acceptable side-effect profiles are needed for this patient population.
1871. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.
作者: Kris V Kowdley.;Eric Lawitz.;Fred Poordad.;Daniel E Cohen.;David R Nelson.;Stefan Zeuzem.;Gregory T Everson.;Paul Kwo.;Graham R Foster.;Mark S Sulkowski.;Wangang Xie.;Tami Pilot-Matias.;George Liossis.;Lois Larsen.;Amit Khatri.;Thomas Podsadecki.;Barry Bernstein.
来源: N Engl J Med. 2014年370卷3期222-32页
An interferon-free combination of the protease inhibitor ABT-450 with ritonavir (ABT-450/r), the nonnucleoside polymerase inhibitor ABT-333, and ribavirin showed efficacy against the hepatitis C virus (HCV) in a pilot study involving patients with HCV genotype 1 infection. The addition of another potent agent, the NS5A inhibitor ABT-267, may improve efficacy, especially in difficult-to-treat patients. This study was designed to evaluate multiple regimens of direct-acting antiviral agents and ribavirin in patients with HCV genotype 1 infection who had not received therapy previously or who had no response to prior therapy with pegylated interferon and ribavirin.
1872. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.
作者: Mark S Sulkowski.;David F Gardiner.;Maribel Rodriguez-Torres.;K Rajender Reddy.;Tarek Hassanein.;Ira Jacobson.;Eric Lawitz.;Anna S Lok.;Federico Hinestrosa.;Paul J Thuluvath.;Howard Schwartz.;David R Nelson.;Gregory T Everson.;Timothy Eley.;Megan Wind-Rotolo.;Shu-Pang Huang.;Min Gao.;Dennis Hernandez.;Fiona McPhee.;Diane Sherman.;Robert Hindes.;William Symonds.;Claudio Pasquinelli.;Dennis M Grasela.; .
来源: N Engl J Med. 2014年370卷3期211-21页
All-oral combination therapy is desirable for patients with chronic hepatitis C virus (HCV) infection. We evaluated daclatasvir (an HCV NS5A replication complex inhibitor) plus sofosbuvir (a nucleotide analogue HCV NS5B polymerase inhibitor) in patients infected with HCV genotype 1, 2, or 3.
1873. Helicase-primase inhibitor pritelivir for HSV-2 infection.
作者: Anna Wald.;Lawrence Corey.;Burkhard Timmler.;Amalia Magaret.;Terri Warren.;Stephen Tyring.;Christine Johnston.;John Kriesel.;Kenneth Fife.;Lawrence Galitz.;Susanne Stoelben.;Meei-Li Huang.;Stacy Selke.;Hans-Peter Stobernack.;Helga Ruebsamen-Schaeff.;Alexander Birkmann.
来源: N Engl J Med. 2014年370卷3期201-10页
Pritelivir, an inhibitor of the viral helicase-primase complex, exhibits antiviral activity in vitro and in animal models of herpes simplex virus (HSV) infection. We tested the efficacy and safety of pritelivir in otherwise healthy persons with genital HSV-2 infection.
1874. Upper-airway stimulation for obstructive sleep apnea.
作者: Patrick J Strollo.;Ryan J Soose.;Joachim T Maurer.;Nico de Vries.;Jason Cornelius.;Oleg Froymovich.;Ronald D Hanson.;Tapan A Padhya.;David L Steward.;M Boyd Gillespie.;B Tucker Woodson.;Paul H Van de Heyning.;Mark G Goetting.;Oliver M Vanderveken.;Neil Feldman.;Lennart Knaack.;Kingman P Strohl.; .
来源: N Engl J Med. 2014年370卷2期139-49页
Obstructive sleep apnea is associated with considerable health risks. Although continuous positive airway pressure (CPAP) can mitigate these risks, effectiveness can be reduced by inadequate adherence to treatment. We evaluated the clinical safety and effectiveness of upper-airway stimulation at 12 months for the treatment of moderate-to-severe obstructive sleep apnea.
1875. A randomized trial of hyperglycemic control in pediatric intensive care.
作者: Duncan Macrae.;Richard Grieve.;Elizabeth Allen.;Zia Sadique.;Kevin Morris.;John Pappachan.;Roger Parslow.;Robert C Tasker.;Diana Elbourne.; .
来源: N Engl J Med. 2014年370卷2期107-18页
Whether an insulin infusion should be used for tight control of hyperglycemia in critically ill children remains unclear.
1876. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.
作者: Valentin Goede.;Kirsten Fischer.;Raymonde Busch.;Anja Engelke.;Barbara Eichhorst.;Clemens M Wendtner.;Tatiana Chagorova.;Javier de la Serna.;Marie-Sarah Dilhuydy.;Thomas Illmer.;Stephen Opat.;Carolyn J Owen.;Olga Samoylova.;Karl-Anton Kreuzer.;Stephan Stilgenbauer.;Hartmut Döhner.;Anton W Langerak.;Matthias Ritgen.;Michael Kneba.;Elina Asikanius.;Kathryn Humphrey.;Michael Wenger.;Michael Hallek.
来源: N Engl J Med. 2014年370卷12期1101-10页
The monoclonal anti-CD20 antibody rituximab, combined with chemotherapeutic agents, has been shown to prolong overall survival in physically fit patients with previously untreated chronic lymphocytic leukemia (CLL) but not in those with coexisting conditions. We investigated the benefit of the type 2, glycoengineered antibody obinutuzumab (also known as GA101) as compared with that of rituximab, each combined with chlorambucil, in patients with previously untreated CLL and coexisting conditions.
1877. A randomized trial of prolonged co-trimoxazole in HIV-infected children in Africa.
作者: Mutsawashe Bwakura-Dangarembizi.;Lindsay Kendall.;Sabrina Bakeera-Kitaka.;Patricia Nahirya-Ntege.;Rosette Keishanyu.;Kusum Nathoo.;Moira J Spyer.;Adeodata Kekitiinwa.;Joseph Lutaakome.;Tawanda Mhute.;Philip Kasirye.;Paula Munderi.;Victor Musiime.;Diana M Gibb.;A Sarah Walker.;Andrew J Prendergast.
来源: N Engl J Med. 2014年370卷1期41-53页
Co-trimoxazole (fixed-dose trimethoprim-sulfamethoxazole) prophylaxis administered before antiretroviral therapy (ART) reduces morbidity in children infected with the human immunodeficiency virus (HIV). We investigated whether children and adolescents receiving long-term ART in sub-Saharan Africa could discontinue co-trimoxazole.
1878. Romosozumab in postmenopausal women with low bone mineral density.
作者: Michael R McClung.;Andreas Grauer.;Steven Boonen.;Michael A Bolognese.;Jacques P Brown.;Adolfo Diez-Perez.;Bente L Langdahl.;Jean-Yves Reginster.;Jose R Zanchetta.;Scott M Wasserman.;Leonid Katz.;Judy Maddox.;Yu-Ching Yang.;Cesar Libanati.;Henry G Bone.
来源: N Engl J Med. 2014年370卷5期412-20页
Sclerostin is an osteocyte-derived inhibitor of osteoblast activity. The monoclonal antibody romosozumab binds to sclerostin and increases bone formation.
1879. Arthroscopic partial meniscectomy versus sham surgery for a degenerative meniscal tear.
作者: Raine Sihvonen.;Mika Paavola.;Antti Malmivaara.;Ari Itälä.;Antti Joukainen.;Heikki Nurmi.;Juha Kalske.;Teppo L N Järvinen.; .
来源: N Engl J Med. 2013年369卷26期2515-24页
Arthroscopic partial meniscectomy is one of the most common orthopedic procedures, yet rigorous evidence of its efficacy is lacking.
1880. Vaccine for prevention of mild and moderate-to-severe influenza in children.
作者: Varsha K Jain.;Luis Rivera.;Khalequ Zaman.;Roberto A Espos.;Chukiat Sirivichayakul.;Beatriz P Quiambao.;Doris M Rivera-Medina.;Pirunghul Kerdpanich.;Mehmet Ceyhan.;Ener C Dinleyici.;Alejandro Cravioto.;Mohammed Yunus.;Pornthep Chanthavanich.;Kriengsak Limkittikul.;Zafer Kurugol.;Emre Alhan.;Adrian Caplanusi.;Serge Durviaux.;Philippe Boutet.;Opokua Ofori-Anyinam.;Vijayalakshmi Chandrasekaran.;Ghassan Dbaibo.;Bruce L Innis.
来源: N Engl J Med. 2013年369卷26期2481-91页
Commonly used trivalent vaccines contain one influenza B virus lineage and may be ineffective against viruses of the other B lineage. We evaluated the efficacy of a candidate inactivated quadrivalent influenza vaccine (QIV) containing both B lineages.
|